Published • loading... • Updated
Indirect Trial Comparison Suggests Retifanlimab Edges Out Avelumab in
Summary by BIOENGINEER.ORG
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Indirect Trial Comparison Suggests Retifanlimab Edges Out Avelumab in
A matching-adjusted indirect comparison of two landmark trials suggests retifanlimab significantly prolongs progression-free survival compared with avelumab in metastatic Merkel cell carcinoma, with favorable numerical trends in overall survival and tumor response.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
